GLP-1 analogues as a new treatment option for hypothalamic obesity in adults: Report of nine cases

European Journal of Endocrinology

Volumn 168, Issue 5, 2013, Pages 699-706

  Zoicas, Flavius ^a   Droste, Michael ^b   Mayr, Bernhard ^a   Buchfelder, Michael ^a   Schöfl, Christof ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b Endocrine Practice   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DESMOPRESSIN; EXENDIN 4; GLIMEPIRIDE; HEMOGLOBIN A1C; HYDROCORTISONE; INSULIN; LEVOTHYROXINE; LIRAGLUTIDE; METFORMIN; METHYLPHENIDATE; RECOMBINANT GROWTH HORMONE; ROSIGLITAZONE; TESTOSTERONE; TESTOSTERONE UNDECANOATE;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; ARTICLE; BODY WEIGHT; BRAIN SURGERY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CRANIOPHARYNGIOMA; DIABETES INSIPIDUS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; DYSLIPIDEMIA; GASTRIC BANDING; GASTROINTESTINAL SYMPTOM; GERM CELL TUMOR; GROWTH HORMONE DEFICIENCY; HAMARTOMA; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; HYPOPITUITARISM; HYPOTHALAMUS TUMOR; LIFESTYLE MODIFICATION; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRITIONAL COUNSELING; OBESITY; PILOCYTIC ASTROCYTOMA; PRIORITY JOURNAL; SATIETY; TONIC CLONIC SEIZURE; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

ADOLESCENT; ADULT; BLOOD GLUCOSE; CRANIOPHARYNGIOMA; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; HYPOTHALAMIC DISEASES; INSULIN RESISTANCE; MALE; MIDDLE AGED; OBESITY; PEPTIDES; PITUITARY NEOPLASMS; VENOMS;

EID: 84877149245     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-12-0997     Document Type: Article

References (52)

1. Karavitaki N, Brufani C, Warner J.T., Adams CB, Richards P, Ansorge O, Shine B., Turner HE & Wass JA. Craniopharyngiomas in children and adults: systematic analysis of 121 cases with long-term follow-up. Clinical Endocrinology 2005 62 397-409. (doi:10.1111/j.1365-2265.2005.02231.x)
2. Karavitaki N, Cudlip S, Adams CB & Wass JA. Craniopharyn-giomas. Endocrine Reviews 2006 27 371-397. (doi:10.1210/er. 2006-0002)
3. Kendall-Taylor P., Jonsson PJ, Abs R, Erfurth E.M., Koltowska-Haggstrom M, Price DA & Verhelst J. The clinical, metabolic and endocrine features and the quality of life in adults with childhood-onset craniopharyngioma compared with adult-onset craniophar-yngioma. European Journal of Endocrinology 2005 152 557-567. (doi:10.1530/eje.1.01877)
4. MÜller H.L., Gebhardt U, Teske C., Faldum A, Zwiener I, Warmuth-Metz M, Pietsch T., Pohl F. Sörensen N & Calaminus G. Post-operative hypothalamic lesions and obesity in childhood craniopharyngioma: results of the multinational prospective trial KRANIOPHARYNGEOM 2000 after 3-year follow-up. European Journal of Endocrinology 2011 165 17-24. (doi:10.1530/EJE-11-0158)
5. Sorva R. Children with craniopharyngioma. Early growth failure and rapid postoperative weight gain. sActa Paediatrica Scandinavica 1988 77 587-592. (doi:10.1111/j.1651-2227.1988.tb10705.x)
6. Stahnke N, Grubel G, Lagenstein I & Willig RP. Long-term follow-up of children with craniopharyngioma. European Journal of Pediatrics 1984 142 179-185. (doi:10.1007/BF00442445)
7. Zoicas F & Schöfl C. Craniopharyngioma in adults. Frontiers in Endocrinology 2012 3 46. (doi:10.3389/fendo.2012.00046)
8. Sklar CA. Craniopharyngioma: endocrine sequelae of treatment. Pediatric Neurosurgery 1994 21 (Suppl 1) 120-123. (doi:10.1159/ 000120873)
9. Daousi C, Dunn AJ, Foy P.M., MacFarlane IA & Pinkney JH. Endocrine and neuroanatomic features associated with weight gain and obesity in adult patients with hypothalamic damage. American Journal of Medicine 2005 118 45-50. (doi:10.1016/j. amjmed.2004.06.035)
10. Harz KJ, MÜller HL, Waldeck E., Pudel V & Roth C. Obesity in patients with craniopharyngioma: assessment of food intake and movement counts indicating physical activity. Journal of Clinical Endocrinology and Metabolism 2003 88 5227-5231. (doi:10.1210/jc.2002-021797)
11. Holmer H, Pozarek G, Wirfalt E., Popovic V, Ekman B, Bjork J & Erfurth EM. Reduced energy expenditure and impaired feeding-related signals but not high energy intake reinforces hypothalamic obesity in adults with childhood onset craniopharyngioma. Journal of Clinical Endocrinology and Metabolism 2010 95 5395-5402. (doi:10.1210/jc.2010-0993)
12. Schöfl C., Schleth A, Berger D., Terkamp C. von zur MÜhlen A & Brabant G. Sympathoadrenal counterregulation in patients with hypothalamic craniopharyngioma. Journal of Clinical Endocrinology and Metabolism 2002 87 624-629. (doi:10.1210/ jc.87.2.624)
13. Mortini P, Losa M, Pozzobon G., Barzaghi R, Riva M, Acerno S., Angius D, Weber G, Chiumello G & Giovanelli M. Neurosurgical treatment of craniopharyngioma in adults and children: early and long-term results in a large case series. Journal of Neurosurgery 2011 114 1350-1359. (doi:10.3171/2010.11. JNS10670)
14. Hoffman HJ, De Silva M, Humphreys RP, Drake JM, Smith ML & Blaser SI. Aggressive surgical management of craniopharyn-giomas in children. Journal of Neurosurgery 1992 76 47-52. (doi:10.3171/jns.1992.76.1.0047)
15. Holmer H, Ekman B, Bjork J., Nordstom CH, Popovic V, Siversson A & Erfurth EM. Hypothalamic involvement predicts cardiovascular risk in adults with childhood onset craniopharyngioma on longterm GH therapy. European Journal of Endocrinology 2009 161 671-679. (doi:10.1530/EJE-09-0449)
16. Pereira AM, Schmid EM, Schutte P.J., Voormolen JH, Biermasz NR, van Thiel SW, Corssmit EP, Smit JW, Roelfsema F & Romijn JA. High prevalence of long-term cardiovascular, neurological and psychosocial morbidity after treatment for craniopharyngioma. Clinical Endocrinology 2005 62 197-204. (doi:10.1111/j.1365-2265.2004.02196.x)
17. BÜlow B., Attewell R, Hagmar L., Malmström P, Nordström CH & Erfurth EM. Postoperative prognosis in craniopharyngioma with respect to cardiovascular mortality, survival, and tumor recurrence. Journal of Clinical Endocrinology and Metabolism 1998 83 3897-3904. (doi:10.1210/jc.83.11.3897)
18. Tomlinson JW, Holden N, Hills R.K., Wheatley K., Clayton RN, Bates AS, Sheppard MC & Stewart PM. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 2001 357 425-431. (doi:10.1016/S0140-6736(00)04006-X)
19. Bereket A, Kiess W, Lustig R.H., MÜller HL, Goldstone A.P., Weiss R., Yavuz Y & Hochberg Z. Hypothalamic obesity in children. Obesity Reviews 2012 13 780-798. (doi:10.1111/j.1467-789X.2012. 01004.x)
20. Greenway FL & Bray GA. Treatment of hypothalamic obesity with caffeine and ephedrine. Endocrine Practice 2008 14 697-703.
21. Lustig RH, Hinds PS, Ringwald-Smith K, Christensen R.K., Kaste SC, Schreiber RE, Rai SN, Lensing SY, Wu S & Xiong X. Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial. Journal of Clinical Endocrinology and Metabolism 2003 88 2586-2592. (doi:10.1210/jc.2002-030003)
22. Mason PW, Krawiecki N & Meacham LR. The use of dextroam-phetamine to treat obesity and hyperphagia in children treated for craniopharyngioma. Archives of Pediatrics & Adolescent Medicine 2002 156 887-892. (doi:10.1001/archpedi.156.9.887)
23. Goldfield GS, Lorello C & Doucet E. Methylphenidate reduces energy intake and dietary fat intake in adults: a mechanism of reduced reinforcing value of food? American Journal of Clinical Nutrition 2007 86 308-315.
24. Askenasy EP, Taber KH, Yang PB & Dafny N. Methylphenidate (Ritalin): behavioral studies in the rat. International Journal of Neuroscience 2007 117 757-794. (doi:10.1080/00207450600 910176)
25. Walker QD, Morris SE, Arrant A.E., Nagel JM, Parylak S, Zhou G, Caster JM & Kuhn CM. Dopamine uptake inhibitors but not dopamine releasers induce greater increases in motor behavior and extracellular dopamine in adolescent rats than in adult male rats. Journal of Pharmacology and Experimental Therapeutics 2010 335 124-132. (doi:10.1124/jpet.110.167320)
26. Elfers CT & Roth CL. Effects of methylphenidate on weight gain and food intake in hypothalamic obesity. Frontiers in Endocrinology 2011 2 78. (doi:10.3389/fendo.2011.00078)
27. Rucker D, Padwal R, Li S.K., Curioni C & Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007 335 1194-1199. (doi:10.1136/bmj.39385. 413113.25)
28. Siebenhofer A, Horvath K, Jeitler K., Berghold A, Stich AK, Matyas E, Pignitter N & Siering U. Long-term effects of weight-reducing drugs in hypertensive patients. Cochrane Database of Systematic Reviews 2009. Article Number CD007654. (doi:10.1002/14651858.CD007654.pub2)
29. Glandt M & Raz I. Present and future: pharmacologic treatment of obesity. Journal of Obesity 2011 2011 636181. (doi:10.1155/ 2011/636181)
30. Inge TH, Pfluger P, Zeller M., Rose SR, Burget L, Sundararajan S, Daniels SR & Tschöp MH. Gastric bypass surgery for treatment of hypothalamic obesity after craniopharyngioma therapy. Nature Clinical Practice. Endocrinology & Metabolism 2007 3 606-609. (doi:10.1038/ncpendmet0579)
31. Page-Wilson G., Wardlaw SL, Khandji AG & Korner J. Hypo-thalamic obesity in patients with craniopharyngioma: treatment approaches and the emerging role of gastric bypass surgery. Pituitary 2012 15 84-92. (doi:10.1007/s11102-011-0349-5)
32. Holst JJ. The physiology of glucagon-like peptide 1. Physiological Reviews 2007 87 1409-1439. (doi:10.1152/physrev.00034. 2006)
33. Apovian CM, Bergenstal RM, Cuddihy R.M., Qu Y., Lenox S, Lewis MS & Glass LC. Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes. American Journal of Medicine 2010 123 468.e9-468.e17. (doi:10.1016/j.amjmed. 2009.11.019)
34. Astrup A, Rössner S, Van Gaal L, Rissanen A, Niskanen L., Al Hakim M, Madsen J, Rasmussen MF & Lean ME. Effects of liraglutide in the treatment of obesity: a randomised, doubleblind, placebo-controlled study. Lancet 2009 374 1606-1616. (doi:10.1016/S0140-6736(09)61375-1)
35. Rosenstock J, Klaff LJ, Schwartz S, Northrup J., Holcombe JH, Wilhelm K & Trautmann M. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care 2010 33 1173-1175. (doi:10.2337/dc09-1203)
36. Vilsboll T, Christensen M, Junker A.E., Knop FK & Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012 344 d7771. (doi:10.1136/bmj.d7771)
37. Abu-Hamdah R., Rabiee A, Meneilly G.S., Shannon RP, Andersen DK & Elahi D. Clinical review: the extrapancreatic effects of glucagon-like peptide-1 and related peptides. Journal of Clinical Endocrinology and Metabolism 2009 94 1843-1852. (doi:10.1210/jc.2008-1296)
38. Barrera JG, Sandoval DA, D'Alessio DA & Seeley RJ. GLP-1 and energy balance: an integrated model of short-term and longterm control. Nature Reviews. Endocrinology 2011 7 507-516. (doi:10.1038/nrendo.2011.77)
39. Larsen PJ, Fledelius C, Knudsen LB & Tang-Christensen M. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes 2001 50 2530-2539. (doi:10.2337/ diabetes.50.11.2530)
40. Tong J & Sandoval DA. Is the GLP-1 system a viable therapeutic target for weight reduction? Reviews in Endocrine & Metabolic Disorders 2011 12 187-195. (doi:10.1007/s11154-011-9170-8)
41. Levy JC, Matthews DR & Hermans MP. Correct homeostasis model assessment (HOMA) evaluation usesthe computer program. Diabetes Care 1998 21 2191-2192. (doi:10.2337/diacare.21.12.2191)
42. Wallace TM, Levy JC & Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004 27 1487-1495. (doi:10.2337/ diacare.27.6.1487)
43. Kalra SP & Kalra PS. Neuroendocrine control of energy homeostasis: update on new insights. Progress in Brain Research 2010 181 17-33. (doi:10.1016/S0079-6123(08)81002-3)
44. Vianna CR & Coppari R. A treasure trove of hypothalamic neu-rocircuitries governing body weight homeostasis. Endocrinology 2011 152 11-18. (doi:10.1210/en.2010-0778)
45. Woods SC & D'Alessio DA. Central control of body weight and appetite. Journal of Clinical Endocrinology and Metabolism 2008 93 S37-S50. (doi:10.1210/jc.2008-1630)
46. Weismann D, Pelka T, Bender G., Jurowich C, Fassnacht M, Thalheimer A & Allolio B. Bariatric surgery for morbid obesity in craniopharyngioma. Clinical Endocrinology 2013 78 385-390. (doi:10.1111/j.1365-2265.2012.04409.x)
47. Bray GM. Exenatide. American Journal of Health-System Pharmacy 2006 63 411-418. (doi:10.2146/ajhp050459)
48. Garber A, Henry R, Ratner R., Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovic M & Bode B. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, doubleblind, parallel-treatment trial. Lancet 2009 373 473-481. (doi:10.1016/S0140-6736(08)61246-5)
49. Lachey JL, D'Alessio DA, Rinaman L, Elmquist J.K., Drucker DJ & Seeley RJ. The role of central glucagon-like peptide-1 in mediating the effects of visceral illness: differential effects in rats and mice. Endocrinology 2005 146 458-462. (doi:10.1210/en. 2004-0419)
50. Ahren B. GLP-1 and extra-islet effects. Hormone and Metabolic Research 2004 36 842-845. (doi:10.1055/s-2004-826173)
51. Alhadeff AL, Rupprecht LE & Hayes MR. GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake. Endocrinology 2012 153 647-658. (doi:10.1210/en. 2011-1443)
52. Willms B, Werner J, Holst J.J., Orskov C., Creutzfeldt W & Nauck MA. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. Journal of Clinical Endocrinology and Metabolism 1996 81 327-332. (doi:10.1210/jc.81.1.327)